Pfizer Inc. (NYSE:PFE) Receives Consensus Rating of “Hold” from Analysts

Share on StockTwits

Shares of Pfizer Inc. (NYSE:PFE) have been given an average recommendation of “Hold” by the fourteen analysts that are presently covering the company, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $43.86.

Several analysts recently commented on the stock. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 target price for the company in a research note on Tuesday, October 1st. UBS Group reissued a “neutral” rating and set a $43.00 target price on shares of Pfizer in a research note on Monday, August 5th. Credit Suisse Group reissued a “hold” rating and set a $41.30 target price on shares of Pfizer in a research note on Wednesday, November 6th. DZ Bank raised shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 target price for the company in a research note on Wednesday, August 28th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Pfizer in a research note on Tuesday, October 29th.

Shares of NYSE:PFE opened at $37.28 on Friday. The company has a 50 day moving average of $36.68 and a 200-day moving average of $39.18. The firm has a market cap of $204.60 billion, a P/E ratio of 12.43, a P/E/G ratio of 3.28 and a beta of 0.67. Pfizer has a twelve month low of $33.97 and a twelve month high of $46.47. The company has a current ratio of 0.90, a quick ratio of 0.68 and a debt-to-equity ratio of 0.55.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.13. Pfizer had a net margin of 30.57% and a return on equity of 28.10%. The company had revenue of $12.68 billion during the quarter, compared to analyst estimates of $12.37 billion. During the same period in the prior year, the business posted $0.78 EPS. The business’s revenue for the quarter was down 4.6% compared to the same quarter last year. Equities research analysts forecast that Pfizer will post 2.96 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a dividend of $0.36 per share. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.86%. Pfizer’s dividend payout ratio is currently 48.00%.

In other news, major shareholder Pfizer Inc purchased 50,000 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $900,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Scott Gottlieb purchased 3,000 shares of the business’s stock in a transaction dated Friday, August 23rd. The shares were purchased at an average price of $34.72 per share, for a total transaction of $104,160.00. Following the acquisition, the director now directly owns 3,000 shares of the company’s stock, valued at $104,160. The disclosure for this purchase can be found here. 0.09% of the stock is owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Weybosset Research & Management LLC increased its stake in Pfizer by 2.0% in the 2nd quarter. Weybosset Research & Management LLC now owns 12,847 shares of the biopharmaceutical company’s stock valued at $557,000 after buying an additional 250 shares during the period. Financial Gravity Wealth Inc. increased its stake in Pfizer by 33.2% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 257 shares during the period. Intl Fcstone Inc. increased its stake in Pfizer by 2.4% in the 2nd quarter. Intl Fcstone Inc. now owns 11,140 shares of the biopharmaceutical company’s stock valued at $483,000 after buying an additional 261 shares during the period. Lee Financial Co increased its stake in Pfizer by 6.2% in the 2nd quarter. Lee Financial Co now owns 4,569 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 265 shares during the period. Finally, Sheets Smith Wealth Management increased its stake in Pfizer by 0.6% in the 3rd quarter. Sheets Smith Wealth Management now owns 47,993 shares of the biopharmaceutical company’s stock valued at $1,724,000 after buying an additional 272 shares during the period. Institutional investors and hedge funds own 71.51% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: How do candlesticks reflect price movement?

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analysts Set $33.00 Target Price for SpringWorks Therapeutics
Analysts Set $33.00 Target Price for SpringWorks Therapeutics
Ardelyx Inc  Given Consensus Rating of “Hold” by Analysts
Ardelyx Inc Given Consensus Rating of “Hold” by Analysts
Western Midstream Partners LP  Receives $32.25 Consensus Price Target from Analysts
Western Midstream Partners LP Receives $32.25 Consensus Price Target from Analysts
SL Green Realty Corp  Receives $93.85 Average Price Target from Brokerages
SL Green Realty Corp Receives $93.85 Average Price Target from Brokerages
HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics
HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics
Analysts Set SS&C Technologies Holdings, Inc.  Price Target at $65.91
Analysts Set SS&C Technologies Holdings, Inc. Price Target at $65.91


© 2006-2019 Ticker Report